# Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis

> **NCT04456803** · PHASE3 · COMPLETED · sponsor: **Sinomune Pharmaceutical Co., Ltd** · enrollment: 239 (actual)

## Conditions studied

- Hyperphosphatemia
- End Stage Renal Disease
- ESRD

## Interventions

- **DRUG:** Ferric citrate tablet
- **DRUG:** Sevelamer carbonate tablet

## Key facts

- **NCT ID:** NCT04456803
- **Lead sponsor:** Sinomune Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-24
- **Primary completion:** 2022-09-13
- **Final completion:** 2022-09-13
- **Target enrollment:** 239 (ACTUAL)
- **Last updated:** 2024-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04456803

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04456803, "Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT04456803. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*